CTLA4 and melanoma: Ipilimumab was the first FDA-approved recombinant humanized anti-CTLA-4 immunoglobulin G1 monoclonal antibody in 2011 for the treatment of advanced melanoma in patients who cannot be surgically cured or have metastasis (Vaddepally et al., 2020).